Pay in 4 interest-free payments of $5.65 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
By Type The GLP-1 receptor agonist market is segmented by drug class into: a) Liraglutide b) Semaglutide c) Tirzepatide d) Dulaglutide e) Other Drugs By Route Of Administration The GLP-1 receptor agonist market is segmented by route of administration into: a) Parenteral b) Oral By End-User The GLP-1 receptor agonist market is segmented by end-user into: a) Hospitals b) Surgical Clinics c) Other End-Users By Geography - The GLP-1 receptor agonist market is segmented by geography into: China India Japan Australia Indonesia South Korea USA Canada Brazil France Germany UK Italy Spain Russia o Asia Pacific o Africa GLP-1 Receptor Agonist Market Drivers The key drivers of the GLP-1 receptor agonist market include: Rise In Obesity Rates During the forecast period, the rise in obesity rates will propel the growth of the GLP-1 receptor agonist market
For Canadians prioritizing a smoother experience with fewer gastrointestinal disruptions, Mazdutide offers compelling advantages worth considering
Semaglutide GLP-1 has proven to be an effective tool for long-term weight loss, particularly for those dealing with obesity
Although a large number of short-term and medium-term clinical studies support the safety and efficacy of GLP-1RAs, there are insufficient data on the presence of delayed side effects with their long-term (decades) use (Guirguis et al., 2024)
